BioRestorative Therapies, Inc. (以下简称"BioRestorative Therapies")近日公布了其主打候选产品BRTX-100在二期临床试验中的盲态数据。数据显示,该疗法在治疗慢性腰椎间盘疾病方面,为患者的疼痛缓解和功能恢复带来了具有临床意义的改善。
此次公布的盲态数据结果令人鼓舞,表明BRTX-100有潜力成为治疗这一困扰众多患者的慢性疾病的重要新选择。公司将继续推进该疗法的临床开发进程。
BioRestorative Therapies, Inc. (以下简称"BioRestorative Therapies")近日公布了其主打候选产品BRTX-100在二期临床试验中的盲态数据。数据显示,该疗法在治疗慢性腰椎间盘疾病方面,为患者的疼痛缓解和功能恢复带来了具有临床意义的改善。
此次公布的盲态数据结果令人鼓舞,表明BRTX-100有潜力成为治疗这一困扰众多患者的慢性疾病的重要新选择。公司将继续推进该疗法的临床开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.